You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 4, 2018

Asia IP: Interview on Pharmaceutical Patent Protection and Challenges

Asia IP

Alan Adcock, partner and deputy director of Tilleke & Gibbins’ intellectual property and regulatory affairs group, Dr. Jakkrit Kuanpoth, of counsel in the firm’s intellectual property group, and Dr. Atthachai Homhuan, manager in the firm’s regulatory affairs group, were recently interviewed by Asia IP  for an article entitled, “Best Feature: The Shape of Pharma,” which covers pharmaceutical patent protection and challenges in the Asian region.

In the article, Alan highlighted that it is important for innovators to prepare risk management plans (RMP) for effective patent protection. He said, “The RMP provides a guideline for when and how a company should conduct prosecution of their invention patent applications, review their applications and patent portfolio, and identify the different weaknesses and strengths of their invention patents.”

Meanwhile, Dr. Jakkrit urged patent holders to regularly monitor for infringing activities to protect their patent rights. “During the life of a patent, the drug patent holder should closely monitor for infringing activities, including vigilant monitoring the Thai Food and Drug Administration’s website for generic pharmaceutical product applications,” he explained.

Dr. Atthachai highlighted the benefits of building a patent portfolio so that pharmaceutical companies can understand and manage their valuable patents. He said, “The integration of a patent portfolio into its business strategy will provide a company with a number of commercial advantages, and provide different channels for fulfilment of business objectives, whether, in M&A, diversification of business units, or licensing of IP technology.”

Alan concluded by sharing that pharmaceutical market growth is shifting toward emerging markets in Asia, including Thailand, where legislative reforms by the Thai government have helped clear the backlog of pharmaceutical patents and improved drug registration processes, making the country increasingly attractive for the pharmaceutical industry.

Asia IP  provides brand owners and law firms with in-depth features, news, and analysis on key developments in Asia’s IP markets. If you would like to read the full article, please visit the Asia IP  website (subscription required).

RELATED INSIGHTS​ 

August 22, 2019
On August 29, Dr. Atthachai Homhuan, manager of Tilleke & Gibbins’ regulatory affairs practice, will be speaking at the CannaBiz Invest Asia Summit in a session entitled “Understanding the Medical Cannabis Investment Landscape & Regulatory Hurdles in Thailand.”
August 19, 2019
Tilleke & Gibbins is happy to share that two of the firm’s practitioners—Alan Adcock, partner and deputy director of intellectual property, and Siraprapha Rungpry, consultant—have been recognized as leading individuals in Who’s Who Legal: Life Sciences 2019 . Notably, only four practitioners in Thailand are listed for this industry, and Tilleke & Gibbins is the only firm housing more than one ranked individual.
July 26, 2019
Partners Thomas J. Treutler and Loc Xuan Le, representing the South-East Asia IPR SME Helpdesk, will speak to business mission delegates from European healthcare and medical device companies at two events in Ho Chi Minh City on July 31 and August 1. The events are part of the EU Business Avenues program, an EU-funded initiative helping European SMEs in various industries to extend their business to Southeast Asian markets.
July 9, 2019
In recognition of Tilleke & Gibbins’ pro bono practice, our firm has been nominated as “2019 Domestic Law Firm of the Year” at this year’s TrustLaw Awards. Our nomination in this category is based on our commitment to supporting pro bono projects through the TrustLaw Foundation over the past year, and is particularly distinctive as Tilleke & Gibbins is one of just three firms in the world, and the only firm in the Asia-Pacific region, under consideration for this award.